Syros Pharmaceuticals Inc (NASDAQ:SYRS) Director Srinivas Akkaraju bought 109,774 shares of Syros Pharmaceuticals stock in a transaction on Thursday, December 14th. The shares were acquired at an average cost of $9.03 per share, with a total value of $991,259.22. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Syros Pharmaceuticals Inc (NASDAQ SYRS) opened at $8.99 on Monday. Syros Pharmaceuticals Inc has a 12-month low of $6.30 and a 12-month high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.53). sell-side analysts predict that Syros Pharmaceuticals Inc will post -2.12 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Nationwide Fund Advisors boosted its position in shares of Syros Pharmaceuticals by 249.8% during the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after acquiring an additional 5,016 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Syros Pharmaceuticals by 17.7% during the third quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock worth $520,000 after acquiring an additional 5,305 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Syros Pharmaceuticals by 167.9% during the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after acquiring an additional 8,399 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Syros Pharmaceuticals during the third quarter worth $133,000. Finally, Ark Investment Management LLC boosted its position in shares of Syros Pharmaceuticals by 114.7% during the second quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock worth $285,000 after acquiring an additional 9,460 shares during the last quarter. Hedge funds and other institutional investors own 58.02% of the company’s stock.

A number of analysts have commented on SYRS shares. Roth Capital started coverage on shares of Syros Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $15.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, JMP Securities upgraded shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a research report on Thursday, September 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.14.

ILLEGAL ACTIVITY WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/18/insider-buying-syros-pharmaceuticals-inc-syrs-director-purchases-991259-22-in-stock.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.